<DOC>
	<DOCNO>NCT01301391</DOCNO>
	<brief_summary>The intent study assess antitumor activity PHA-848125AC patient recurrent metastatic , unresectable malignant thymoma previously treat multiple line chemotherapy .</brief_summary>
	<brief_title>Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy</brief_title>
	<detailed_description>This single-arm , open-label , multicenter , phase II clinical trial design early stopping rule . PHA-848125AC administered patient recurrent metastatic unresectable B3 thymoma thymic carcinoma receive one line prior systemic therapy advance / metastatic disease . The intent study assess antitumor activity PHA-848125AC ultimately improve outcome patient . The primary end point study progression free survival rate 3 month .</detailed_description>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Signed date IRB/Approved Informed Consent Histologically cytologically proven diagnosis unresectable B3 thymoma thymic carcinoma recurrent progress one prior systemic therapy advance / metastatic disease Presence measurable disease Age &gt; =18 year old ECOG performance status 01 Negative pregnancy test ( female reproductive year ) Use effective contraceptive method men woman child produce potential Adequate liver function Total Serum Bilirubin &lt; =1.5 x upper limit normal ( ULN ) Transaminases ( AST/ALT ) &lt; =2.5ULN ( liver metastasis present , &lt; =5ULN allow ) ALP &lt; =2.5ULN ( liver and/or bone metastasis present , &lt; =5ULN allow ) Adequate renal function Serum Creatinine &lt; =ULN Creatinine Clearance calculate Cockcroft Gault 's formula &gt; 60 mL/min Adequate hematologic status ANC &gt; =1,500cells/mm3 Platelet Count &gt; = 100,000cells/mm3 Hemoglobin &gt; =9.0g/dL Two week must elapse since completion prior chemotherapy , minor surgery , radiotherapy ( provide 25 % bone marrow reserve irradiate ) Resolution acute toxic effect prior treatment NCI CTC ( Version 3.0 ) grade &lt; =1 Any follow past 6 month : myocardial infarction , uncontrolled cardiac arrhythmia , unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis Grade &gt; 1 retinopathy Known brain metastasis Known active infection Pregnant breast feed woman Diabetes mellitus uncontrolled Gastrointestinal disease would impact drug absorption Patients treatment anticoagulant coagulation disorder sign hemorrhage baseline Patients previous history current presence neurological disorder ( exception myasthenia gravis ) , include epilepsy ( although control anticonvulsant therapy ) , Parkinson 's disease extrapyramidal syndrome . Other severe acute chronic medical psychiatric condition laboratory abnormality make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>B3 C malignant thymoma</keyword>
</DOC>